Evidence map›Paper›PMID 34262052›Full record

ArticleNPJ vaccines2021

Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.

Nadine G Rouphael, Lilin Lai, Sonia Tandon, Michele Paine McCullough, Yunchuan Kong, Sarah Kabbani, Muktha S Natrajan, Yongxian Xu, Yerun Zhu, Dongli Wang and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025
    Review
  8. Article
  9. Article
  10. Exploiting Unique Features of Microneedles to Modulate Immunity.Advanced materials (Deerfield Beach, Fla.) · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Nadine G RouphaelHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia. nroupha@emory.edu.
Lilin LaiEmory Vaccine Center, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia.
Sonia TandonHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Michele Paine McCulloughHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Yunchuan KongLaney Graduate School, Emory University, Atlanta, Georgia.
Sarah KabbaniHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Muktha S NatrajanHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Yongxian XuHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Yerun ZhuHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Dongli WangHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Jesse O'SheaHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Amy ShermanHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Tianwei YuLaney Graduate School, Emory University, Atlanta, Georgia.
Sebastien HenryMicron Biomedical, Inc., Atlanta, Georgia.
Devin McAllisterMicron Biomedical, Inc., Atlanta, Georgia.ORCID http://orcid.org/0000-0003-4456-3940
Daniel StadlbauerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Surender KhuranaDivision of Viral Products Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
Hana GoldingDivision of Viral Products Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4121-776X
Mark J MulliganNew York University Langone Medical Center, Alexandria Center for Life Sciences, New York, NY, USA.
Mark R PrausnitzMicron Biomedical, Inc., Atlanta, Georgia.ORCID http://orcid.org/0000-0002-9076-8448
Emory University · USCenter for Biologics Evaluation and Research · USIcahn School of Medicine at Mount Sinai · USMicron Biomedical (United States) · USGeorgia Institute of Technology · USNYU Langone Health · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
Influenza vaccination using a microneedle patchU01EB012495 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2010 to 2015
$9.6M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
Broad humoral protection induced by influenza B neuraminidase-based immunogensR01AI117287 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2016 to 2020
$2.4M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI117287NIAID NIH HHS T32 AI074492NIBIB NIH HHS U01 EB012495
6 · The paper itself

Abstract

In a phase 1 randomized, single-center clinical trial, inactivated influenza virus vaccine delivered through dissolvable microneedle patches (MNPs) was found to be safe and immunogenic. Here, we compare the humoral and cellular immunologic responses in a subset of participants receiving influenza vaccination by MNP to the intramuscular (IM) route of administration. We collected serum, plasma, and peripheral blood mononuclear cells in 22 participants up to 180 days post-vaccination. Hemagglutination inhibition (HAI) titers and antibody avidity were similar after MNP and IM vaccination, even though MNP vaccination used a lower antigen dose. MNPs generated higher neuraminidase inhibition (NAI) titers for all three influenza virus vaccine strains tested and triggered a larger percentage of circulating T follicular helper cells (CD4 + CXCR5 + CXCR3 + ICOS + PD-1+) compared to the IM route. Our study indicates that inactivated influenza virus vaccination by MNP produces humoral and cellular immune response that are similar or greater than IM vaccination.

Identifiers

PMID34262052
PMCPMC8280206
OpenAlexW3178068647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.